Range Cancer Therapeutics ETFCNCR
Type
ETF
Peer group
Alternative
Net assets
$8.9M
Expense ratio
—
1-year return
-33.3%
3 years, a year
-14.9%
5 years, a year
-10.6%
More on CNCR.
- CNCR overview
- CNCR holdings
- CNCR risk
- CNCR costs
- CNCR money in and out
- CNCR share classes
- Compare CNCR with other funds
Returns after fees, from the fund's SEC filings up to Feb 2025. Past returns are not a promise. Not financial advice.